June 2026 Activities Report and Appendix 4C

Highlights of the Quarter

- Cash and term deposit balance of $9.03 million at 30 June 2026
- Phase 2a enrolment accelerated, with 14 patients enrolled during the quarter to reach 26 patients at 30 June 2026; subsequent to quarter end a further two patients were enrolled, taking total enrolment to 28 patients
- Appointment of Dr Rosalind Wilson as Chief Medical Officer announced in June 2026, effective 13 July 2026
- Global clinical footprint sites in Australia, United States and Italy – with work progressing to open additional sites in France
- CEO attended the European Hematology Association (EHA) 2026 Congress in Stockholm and the BIO International Convention in San Diego, engaging with haematology experts, Phase 2a investigators and prospective partners
- Join CEO, James McDonnell, for an online investor briefing on Monday, 3rd August at 11am (AEST). Register here: https://prescienttherapeutics.investorportal.com.au/investor-briefing/

MELBOURNE, Australia – 27 July 2026 – Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing targeted therapies for cancer, is pleased to provide its Appendix 4C cash flow statement and Activities Report for the quarter ended 30 June 2026. The quarter was marked by strong momentum in the PTX-100 Phase 2a study, with enrolment increasing to 26 patients, alongside extensive engagement with investigators and prospective partners across Europe and the United States.

Financial summary

Prescient ended the quarter with cash reserves of $9.03 million (March 2026: $7.93 million). Net operating cash outflows totalled $2.87 million including $1.80 million invested in R&D and clinical activities. R&D and clinical expenditure included payments relating to prior quarters. As noted in the March 2026 quarterly report, these payments were delayed due to the late receipt of invoices from a key clinical services provider and were subsequently settled during the current quarter.

Payments to related parties and their associates, being fees payable to non-executive directors, totalled $85,000.

PTX-100 clinical program

The Phase 2a trial has a global footprint with sites in Australia, the United States and Italy. Work is progressing to open additional sites in France. Fourteen patients were enrolled during the quarter, bringing total enrolment to 26 patients at 30 June 2026. Following quarter end, a further two patients were

enrolled, increasing enrolment to 28 patients. The study protocol provides for the enrolment of up to 40 patients in the Phase 2a component.

Based on current enrolment trends, the Company expects a Dose Optimisation Committee meeting to be held before the end of 2026 in accordance with the study protocol. The committee is expected to assess safety data and provide guidance on continuation of the study.

The Phase 1b study remains closed. One patient continues to receive PTX-100 on a compassionate access basis, consistent with the clinical response previously observed.

European engagement and EHA 2026 Congress

During the quarter, the CEO travelled to Europe to support ongoing recruitment for the PTX-100 Phase 2a study and to strengthen relationships with clinical investigators across the Company's expanding European network.

Mr McDonnell also attended the European Hematology Association (EHA) 2026 Congress in Stockholm, where he met with leading haematology experts and investigators involved in the PTX-100 program. This included discussions with Professor Luigi Zinzani, Professor of Hematology and Head of the Lymphoma Group at the University Hospital of Bologna, and a Principal Investigator on the PTX-100 Phase 2a trial.

Professor Zinzani noted that there remains significant room to improve outcomes for patients with Cutaneous T-Cell Lymphoma (CTCL) and expressed optimism about the potential of PTX-100's novel approach both as a standalone therapy and in combination strategies.

Broader development opportunities

Prescient continues to assess opportunities to generate further clinical data for PTX-100 in Peripheral T-Cell Lymphoma (PTCL). Additional studies will be considered following selection of the recommended Phase 2 dose for CTCL.

Corporate and business development

In June 2026, Chief Executive Officer James McDonnell attended the BIO International Convention in San Diego, one of the largest gatherings of the global biotechnology industry, bringing together industry leaders, investors and prospective partners. Mr McDonnell met with prospective partners as the Company advances PTX-100, understood to be the only GGTase-1 inhibitor in the world in clinical development.

The Company continued to progress business development discussions relating to its OmniCAR and CellPryme platforms, with partner engagement remaining a strategic focus throughout the quarter.

During the quarter, Prescient announced the appointment of Dr Rosalind Wilson as Chief Medical Officer, effective 13 July 2026. Dr Wilson is a global oncology drug development leader with more than 30 years'

experience spanning clinical development, regulatory strategy and executive leadership. As Chief Medical Officer, Dr Wilson leads Prescient's clinical development strategy and execution, including advancement of PTX-100 in its Phase 2 CTCL study and progression of the broader pipeline.

"I am excited to join Prescient at such an important stage in its development. The Company's pipeline represents a compelling opportunity to deliver meaningful benefit to patients with cancer. I look forward to working with the team to advance these programs and unlock their full potential," said Dr Wilson.

Join a briefing

Join CEO, James McDonnell, for an online investor briefing on Monday, 3rd August at 11am (AEST). Register here: https://prescienttherapeutics.investorportal.com.au/investor-briefing/

- ENDS -

This announcement has been approved by the Board of Prescient Therapeutics Limited.

For more information please contact:

Company enquiries
James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor enquiries
Patrick Nelson
Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (ASX:PTX)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100 is a first-in-class compound with the ability to block an enzyme that can contribute to cancer growth known as geranylgeranyl transferase-1 (GGTase-1). Blocking this target disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral signaling circuits in cancer cells, leading to their apoptosis (death). Mutations in Ras pathways are believed to be involved in up to 22% of all cancers. PTX-100 is understood to be the only GGTase-1 inhibitor in the world in clinical development.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and in a recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T-cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the Phase 2a part of the trial.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Prescient Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
56 006 569 106	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(1,801)	(7,019)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(470)	(1,842)
	(f) administration and corporate costs*	(663)	(2,838)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	61	94
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	4,366
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,873)**	**(7,239)**

** During the quarter ended 31 March 2026, the Company retrospectively reclassified $49,000 of expenditure from administrative and corporate costs to lease payments (Section 3.9) to maintain consistency with the presentation of the 31 December 2025 Half Year Financial Report.*

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(g) entities	-	-
	(h) businesses	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
	(i) property, plant and equipment	-	-
	(j) investments in term deposits with maturities longer than 3 months at acquisition*	4,000	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments (term deposits)	-	-
	(e) intellectual property	-	-
	(f) Other	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**4,000**	**-**

** The Company's $4 million term deposits were renewed into deposits with maturities of less than three months. Accordingly, they are classified as cash and cash equivalents as at 30 June 2026.*

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	9,848
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(636)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Repayment of lease liability and amount received under loan funded share arrangement) *	(30)	161
3.10	**Net cash from / (used in) financing activities**	**(30)**	**9,373**

Consolidated statement of cash flows	Current quarter $A'000	Year to date (12 months) $A'000
** During the quarter ended 31 March 2026, the Company retrospectively reclassified $49,000 of expenditure from administrative and corporate costs to lease payments (Section 3.9) to maintain consistency with the presentation of the 31 December 2025 Half Year Financial Report.*		

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	7,931	6,908
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,873)	(7,239)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	4,000	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(30)	9,373
4.5	Effect of movement in exchange rates on cash held	-	(14)
4.6	**Cash and cash equivalents at end of period**	**9,028**	**9,028**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	3,028	5,931
5.2	Call deposits	6,000	2,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**9,028**	**7,931**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	85
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Term Deposits) *	-	4,000
7.4	**Total financing facilities**	**-**	**4,000**

7.5	**Unused financing facilities available at quarter end**	-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

** The Company's $4 million term deposits were renewed into deposits with maturities of less than three months. Accordingly, they are classified as cash and cash equivalents as at 30 June 2026.*

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,873)
8.2	Cash and cash equivalents at quarter end (item 4.6)	9,028
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	9,028
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**3.14**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: N/A

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 27 July 2026

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.